Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Preferred Shares (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Preferred Shares for 13 consecutive years, with $18000.0 as the latest value for Q4 2025.

  • Quarterly Preferred Shares fell 89.41% to $18000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18000.0 through Dec 2025, down 89.41% year-over-year, with the annual reading at $18000.0 for FY2025, 89.41% down from the prior year.
  • Preferred Shares hit $18000.0 in Q4 2025 for Guided Therapeutics, down from $32000.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $1.6 million in Q4 2021 to a low of $18000.0 in Q4 2025.
  • Historically, Preferred Shares has averaged $471684.2 across 5 years, with a median of $475000.0 in 2023.
  • Biggest five-year swings in Preferred Shares: soared 698.1% in 2023 and later plummeted 93.26% in 2025.
  • Year by year, Preferred Shares stood at $1.6 million in 2021, then tumbled by 70.16% to $489000.0 in 2022, then surged by 71.37% to $838000.0 in 2023, then crashed by 79.71% to $170000.0 in 2024, then crashed by 89.41% to $18000.0 in 2025.
  • Business Quant data shows Preferred Shares for GTHP at $18000.0 in Q4 2025, $32000.0 in Q2 2025, and $61000.0 in Q1 2025.